The constitutive androstane receptor (CAR) activates the expression of a reporter gene attached to the phenobarbitalresponse element (PBRE) of the cytochrome P450 2B1 (CYP2B1) gene in response to the barbiturate phenobarbital and the plant product picrotoxin. The xenobiotic-mediated increase in transactivation occurs in transfected primary hepatocytes and in liver transfected by biolistic-particle-mediated DNA transfer, but not in the transformed cell lines HepG2, CV-1 and HeLa, which support only constitutive activation of gene expression by CAR. Steroid co-activator 1 (SRC-1) enhances both constitutive and xenobiotic-induced CAR-mediated transactivation via the CYP2B1 PBRE in transfected primary hepatocytes. The nuclear receptor 1 (NR1) site of the PBRE is sufficient for CAR-
INTRODUCTION
A vast array of foreign chemicals, including dietary components, environmental pollutants and therapeutic drugs, require detoxification to ensure their safe elimination from the body. The initial stage in the detoxification of xenobiotics is usually carried out by cytochromes P450 (CYPs), in particular by members of the CYP1, CYP2, CYP3 and CYP4 families. The efficiency of this process is enhanced because many foreign chemicals selectively induce, via activation of gene transcription, the CYP required for their metabolism (reviewed in [1] ).
Transcriptional activation of CYP genes by xenobiotics occurs predominantly in the liver and is mediated by the interaction of ligand-nuclear-receptor complexes with enhancer sequences that lie upstream of CYP gene promoters (reviewed in [2] [3] [4] ). Polycyclic aromatic hydrocarbons increase the expression of CYP1 genes via the aryl hydrocarbon (Ah) receptor (reviewed in [5, 6] ). The peroxisome-proliferator-activated receptor α [7] mediates regulation of CYP4 genes by drugs, such as clofibrate, and nongenotoxic carcinogens [8] . The pregnane X receptor [9] , also known as the steroid and xenobiotic receptor [10] , activates CYP3 genes by binding natural and synthetic steroids.
Less well understood, however, are the mechanisms by which CYP2B genes are regulated in response to numerous structurally diverse compounds, including the anti-epileptic and tumour promoter phenobarbital [11] [12] [13] , and plant products, such as picrotoxin [14] and the pinenes camphor and limonene [15] . A phenobarbital-response element (the PBRE) was first identified upstream (k2318 to k2155 bp) of the rat CYP2B2 gene [16] , and a similar sequence upstream of the mouse Cyp2b10 gene was shown subsequently to confer inducibility, by 16 different compounds, on a reporter gene transfected into mouse primary hepatocytes [17] . Within the PBRE are two nuclear-receptor direct-repeat (DR) 4 (where the 4 denotes 4 bp spacing) -binding sites of the type AGGTCA [18] , known as nuclear receptor 1 (NR1) and NR2 [19] , separated by a nuclear factor 1 (NF1) site [20] . The identification, in i o, of a phenobarbital-dependent DNA footprint in the region of the PBRE [21] , and the increase in i o, in response to phenobarbital, of the expression of a reporter gene attached to the PBRE [22] , confirm a role for this sequence in the induction of CYP2B genes by phenobarbital. The orphan nuclear receptor constitutive androstane receptor (CAR) [23, 24] has been shown to bind to the PBRE as a heterodimer with the retinoid X receptor α (RXRα) [19] . CAR, unlike other nuclear receptors, is able to bind to its response element and activate transcription in the absence of ligand [24] . In the absence of any exogenous chemical, CAR increases the transcription of a reporter gene, linked to the PBRE, in the hepatoma cell line HepG2 [19] . The constitutive activity of CAR is inhibited by androstanol (5α-androstan-3α-ol) and androstenol (5α-androst-16-en-3α-ol), because these compounds promote the release of the co-factor steroid co-activator 1 (SRC-1) from the putative ligand-binding domain of CAR [25] . Interestingly, in HepG2 cells the ability of CAR to transactivate a CYP2B6 PBRE reporter-gene construct is lost after treatment of cells with androstenol, but is restored following subsequent treatment with phenobarbital [26] . It has been suggested that phenobarbital causes CAR to translocate from the cytoplasm to the nucleus, where the receptor is then able to activate the transcription of CYP2B genes [27] .
In this report we show directly that, in primary hepatocytes and intact liver, CAR-mediated transactivation of CYP2B1 gene expression via the PBRE is activated by phenobarbital and picrotoxin. This xenobiotic-induced enhancement of transcription by CAR does not require pretreatment with an inverse agonist of the receptor and is not observed in transformed cell lines. In addition, we demonstrate that the transactivation of CYP2B1 gene expression by CAR is greatly stimulated by the transcription factor Sp1 [28] and by the co-activator SRC-1 [20] .
MATERIALS AND METHODS

Plasmids
A plasmid containing nucleotides k3878 to j27 of the CYP2B1 gene was provided by Dr P. Shaw (PanVera Corporation, Madison, WI, U.S.A.). The reporter plasmid (CYP2B1 PBRE)-SV40-luc was constructed by inserting a Sau3A fragment, comprising nucleotides k2301 to k2142 of the CYP2B1 5h-flanking sequence, into the BglII site of the plasmid pGL3-SV40-Promoter (Promega). This placed the CYP2B1 gene PBRE upstream of the firefly luciferase reporter gene. The reporter plasmid (CYP2B1 NR1) # -SV40-luc was constructed by inserting two copies of a double-stranded oligonucleotide (5h-TCTGTA-CTTTCCTGACCTT-3h), containing the NR1 site of the CYP2B1 PBRE, into the SmaI site of the plasmid pGL3-SV40-Promoter. The reporter plasmid (CYP2B1PP)-luc was constructed by inserting a StuI\HindIII fragment, corresponding to the region from k179 to k1 of the CYP2B1 gene, which contains the minimal promoter, into the pGL3 Basic vector (Stratagene). The plasmid (CYP2B1PBRE)-PP-luc was constructed by inserting a Sau3A1-fragment (k2301 to k2142 of the CYP2B1 gene) into the BamHI site of the plasmid (CYP2B1PP)-luc. The plasmid pRL-TK (Promega), which contains the renilla luciferase gene under the control of the thymidine kinase promoter, was used as a control vector to normalize the results of transient-transfection assays. Expression plasmids for mouse CAR (cDM8-mCARβ), mouse RXR (pSG5-mRXRα), steroid receptor co-activator (pSG5-SRC-1) and Sp1 (CMVSP1pBluescript) were provided, respectively, by Professor D. 
Cell culture and transfection
Primary rat hepatocytes were prepared by a two-step collagenaseperfusion method [29] . After attachment, cells were cultured in William's E medium, supplemented with 10 % foetal calf serum, 
In vivo transfection of liver by biolistic particle delivery
Gold particles (25 mg, 1 µm ; Bio-Rad), were coated with 100 µg of DNA. The proportions of (CYP2B1 PBRE)-SV40-luc, pRL-TK and the expression plasmid cDM8-mCARβ were 10 : 1 : 1. The amount of total DNA per cartridge was 2 µg. Male Sprague-Dawley rats (200-250 g) were anaesthetized with ketamine (100 mg\kg of body weight) and xylazine (70 mg\kg). The abdominal area was shaved and opened to expose the liver. DNA-coated gold particles were delivered into the liver under a He pressure of 250 psi (1725 kPa). The liver was shot at two different positions in a single lobe. A single dose of phenobarbital (100 mg\kg) was given intraperitoneally, as soon as suturing was complete. Later (24 h) the liver was removed and the shot areas assayed for luciferase activity as above.
RNA analysis
Total RNA was isolated as described previously [30] from cultures of rat hepatocytes that were either untreated or had been treated with phenobarbital or picrotoxin. RNase protection assays were carried out as described previously [31] .
Protein extracts for gel mobility-shift assays
Male Sprague-Dawley rats (200-250 g) were either untreated or treated with phenobarbital as described previously [30] . Liver nuclear protein extracts were prepared according to the method of Sierra [32] , as described previously [33, 34] and stored at k70 mC. Protein concentration was measured by the method of Lowry, and protein integrity was assessed by SDS\PAGE.
Gel mobility-shift assays
CAR and RXRα were synthesized in itro using a TNT2 transcription\translation-coupled reticulocyte lysate system (Promega) according to the supplier's recommendations. Gel mobility-shift assay mixtures contained 10 mM Hepes (pH 7.6), 0.5 mM dithiothreitol, 15 % (v\v) glycerol, 2.5 µg of poly(dI:dC), 0.05 % (v\v) Nonidet P-40, 50 mM NaCl, 1.5 µl of in itro-translated products or 5 µg of nuclear protein extract, and 3i10% c.p.m. of a $#P-labelled double-stranded oligonucleotide. The binding reaction was performed at room temperature for 20 min. Competition assays were performed with a 100-fold molar excess of unlabelled double-stranded oligonucleotide. The following double-stranded oligonucleotides were used as probes or competitors : NR1 (DR4), 5h-TCGATCTGT-ACTTTCCTGACCTT-3h ; NR2 short (DR4), 5h-TCGACATC-AACTTGACTGACACCA-3h ; NR2 long (DR4), 5h-TCGACC-ACCATCAACTTGACTGACACCAGGA-3h ; RXRα-binding site (DR1), 5h-TCGAAGCTTCAGGTCAGAGGTCAGAGA-GCT-3h ; NF1, 5h-TCGATTTTGGATTGAAGCCAATATGATA3h ; CYP2B1 (k88\k66), 5h-TCGATAGCTAAAGCAGGA-GGCGTGAAC-3h ; CYP2B1 (k48\k26), 5h-TCGATGAGTG-GAGGGGCGGATTCAGCA-3h ; Sp1, 5h-TCGAATTCGATC-GGGGCGGGGCGAGC-3h. Only the sequences of the upperstrand oligonucleotides are shown. The 4 bp, 5h-TCGA-3h, present at the 5h end of each oligonucleotide (upper and lower strands) was included as non-specific flanking sequence. Doublestranded oligonucleotides were formed by annealing overlapping complementary single-stranded sequences (synthesized by Amersham Pharmacia Biotech), and radiolabelled by filling-in the 5h TCGA overhangs through the use of the Klenow fragment of Escherichia coli DNA polymerase. For supershift assays, rabbit polyclonal antibodies against RXRα (SC-553x ; 2 µg) or NF1 (SC-870x ; 2 µg ; Santa Cruz Biotechnology) were added 15 min after the start of the binding reaction. Incubation was continued for another 20 min.
RESULTS
Xenobiotics increase the transactivation of CYP2B1 by CAR in primary hepatocytes and liver but not in transformed cell lines
Primary rat hepatocytes were transiently transfected with a reporter plasmid, containing one copy of the CYP2B1 PBRE upstream of the SV40 promoter and the firefly luciferase gene [(CYP2B1 PBRE)-SV40-luc], alone or together with an expression vector for mouse CAR. Measurement of luciferase activity showed that CAR stimulated transcription of the reporter gene 5-fold (Figure 1a) . Treatment of transfected cells with the barbiturate phenobarbital or the natural plant product picrotoxin increased reporter-gene expression 4-and 9-fold, respectively, above that obtained as a result of constitutive transactivation by CAR (Figure 1a) . However, when either the pGL3 Basic vector or the pGL3-SV40-Promoter vector was used as a reporter construct, co-transfected CAR had no effect on reporter-gene expression, in either the presence or absence of phenobarbital or picrotoxin (results not shown).
Transcription of a reporter gene under the control of the PBRE upstream of a CYP2B1 minimal promoter was stimulated about 3-fold by CAR and was increased a further 5-fold in response to phenobarbital (see Figure 6 below). Therefore, in primary hepatocytes, CAR supports both constitutive and xenobiotic-induced transactivation of reporter-gene expression via the CYP2B1 PBRE.
Co-transfection of HepG2 cells with the CAR expression vector and the reporter plasmid (CYP2B1 PBRE)-SV40-luc resulted in a 2-fold stimulation of reporter-gene expression above that obtained in cells transfected with the reporter plasmid alone (Figure 1b) . However, in contrast to the situation in primary hepatocytes, treatment of this liver-derived cell line with phenobarbital resulted in no further activation of reporter-gene transcription. Similarly, two non-liver-derived cell lines, CV-1, a cell line much used for nuclear-receptor-mediated transactivation studies, and HeLa, were able to support constitutive CARmediated transactivation via the PBRE, 2.5-and 19-fold, respectively, but were unable to support a further increase in reporter-gene expression in response to phenobarbital (Figures  1c and 1d) . In fact, treatment of HeLa cells with phenobarbital consistently decreased the constitutive activation of the luciferase reporter gene by CAR (Figure 1d ). To confirm that activation of CAR by phenobarbital occurs in i o, rat liver was transfected, via biolistic-particle-mediated DNA transfer, with (CYP2B1 PBRE)-SV40-luc alone or together with a CAR expression vector. Luciferase activity was measured 24 h post-operation in phenobarbital-treated and untreated animals. Reporter-gene activity was stimulated by CAR and was increased a further 2.5-fold in response to phenobarbital (Figure 1e ).
The co-activator SRC-1 stimulates both constitutive and xenobiotic-induced CAR activation of transcription via the CYP2B1 PBRE
CAR enhancement of transcription is mediated by the coactivator SRC-1 in a ligand-independent manner in CV-1 cells [25] . It was of interest, therefore, to determine whether SRC-1 stimulated CAR-mediated transactivation of reporter-gene expression, via the CYP2B1 PBRE, in primary hepatocytes. Cells were co-transfected with the (CYP2B1 PBRE)-SV40-luc reporter plasmid and expression plasmids for SRC-1 and\or CAR ( Figure  2a) . Reporter activity was increased 3-fold by SRC-1, 5-fold by CAR and 16-fold when both SRC-1 and CAR were present. Phenobarbital and picrotoxin caused further 2-and 3.6-fold increases, respectively, in reporter-gene expression when SRC-1 was co-expressed with CAR. Thus both constitutive and xenobiotic-induced CAR activation of transcription via the CYP2B1 PBRE are stimulated by SRC-1. When the reporter plasmid used was (CYP2B1 NR1) # -SV40-luc, which contains only the NR1 site of the CYP2B1 PBRE, CAR-mediated activation of reporter-gene expression was maintained, but could not be stimulated by SRC-1 (Figure 2b ). Thus the NR1 site is sufficient to support CAR-mediated transactivation, but sequences other than the NR1 element within the PBRE are required for the stimulation of this activation by SRC-1.
The CYP2B1 PBRE comprises two nuclear-receptor-binding sites, NR1 and NR2, separated by an NF1-binding site [19] . Each nuclear-receptor site has two direct-repeat half-sites separated by four nucleotides. Rat liver nuclear proteins formed a complex in a gel mobility-shift assay with the NR1 sequence and with either of two oligonucleotides containing the NR2 sequence of the CYP2B1 PBRE (NR2 short, 5h-TCGACATCAACTTGACT-
Figure 3 NR1 and NR2 sites of the CYP2B1 PBRE bind different proteins
Gel mobility-shift assays using as probe a 32 P-labelled double-stranded oligonucleotide corresponding to either the NR1 or NR2 site of the CYP2B1 PBRE (as indicated). (a) Liver nuclear proteins (5 µg) isolated from phenobarbital-treated rats were assayed in the presence (j) or absence (k) of a 100-fold molar excess of an unlabelled double-stranded oligonucleotide competitor corresponding to the NR1 or NR2 site of the PBRE, or to a consensus RXRα-binding site. (b) Liver nuclear-protein extracts (NE, 5 µg) isolated from either untreated (U) or phenobarbital-treated (PB) rats were assayed in the presence (j) or absence (k) of antibodies to RXRα or NF1. (c) Mouse CAR (mCAR-β) and RXRα, produced by in vitro transcription/translation, were assayed in the presence (j) or absence (k) of an antibody against RXRα or of a 100-fold molar excess of an unlabelled double-stranded oligonucleotide competitor corresponding to the NR1, NR2 or NF1 site of the PBRE.
GACACCATCGA-3h, and NR2 long, 5h-TCGACCACCATC-AACTTGACTGACACCAGGATCGA-3h ; Figure 3a and results not shown). An excess of an oligonucleotide for NR1 did not compete for proteins bound to the NR2 and vice versa. However, an oligonucleotide containing a consensus binding site for RXRα competed for proteins bound to either NR1 or NR2 (Figure 3a ). An antibody against RXRα was able to supershift DNA-protein complexes formed between both NR1 and NR2 and liver nuclear proteins isolated from untreated or phenobarbital-treated rats, whereas an antibody against NF1 (used as a control) had no effect (Figure 3b ). Gel-shift assays of proteins produced by in itro transcription\translation ( Figure  3c and results not shown) showed that when present alone, neither CAR nor RXRα could bind to the NR1 or the NR2 site. However, when both proteins were present a complex was formed on the NR1, but not the NR2 site (irrespective of whether the short or long NR2 oligonucleotide was used as a probe ; Figure 3c and results not shown). This complex was competed by an excess of NR1, but not by NR2 (Figure 3c ) or by oligonucleotides containing either the NF1 site of the CYP2B1 CYP2B1 gene regulation by CAR, SRC-1 and Sp1
Figure 4 Phenobarbital and picrotoxin induction of CYP2B1 mRNA
Time course of CYP2B mRNA induction in primary hepatocytes. Total RNA was isolated at various times from untreated cells (U), or from cells treated with 0.1 mM phenobarbital (PB) or 0.5 mM picrotoxin (PCX). CYP2B1 mRNA was assayed by RNase protection. Figure 3c ) or a consensus Sp1 site (results not shown), and was supershifted by an antibody against RXRα (Figure 3c ). Taken together, the results demonstrate that CAR binds, as a heterodimer with RXRα, to the NR1 site of the CYP2B1 PBRE, whereas the NR2 site interacts with other proteins, including RXRα heterodimerized with an unknown partner.
PBRE (
Both phenobarbital and picrotoxin are potent inducers of CYP2B1 in the liver, each compound increasing CYP2B1 mRNA by more than 50-fold [14, 30] . A time course of CYP2B mRNA induction in primary hepatocyte cultures shows that the kinetics of induction by the two compounds are very similar (Figure 4 ). This suggests that phenobarbital and picrotoxin induce CYP2B gene expression via the same activation pathway. However, the level of expression of a reporter gene under the control of the CYP2B1 PBRE is greater in response to picrotoxin than to phenobarbital (Figures 1a and 2a) . The NR1 site of the PBRE is sufficient to support both constitutive and phenobarbital-induced CAR-mediated transactivation of gene expression, but not the increased induction in response to picrotoxin (Figures 2a and 2b) , which requires additional sequences of the PBRE, i.e. the NF1 or NR2 sites.
The transcription factor Sp1 stimulates both basal and xenobioticinduced transcription of CYP2B1
The proximal promoters of several CYP genes contain a sequence, the basal transcription element (BTE), which has been shown to confer transcriptional activity on the CYP1A1 gene [35] . Two proteins bind to the CYP1A1 BTE, Sp1 and BTE-binding protein [35] . Mutation of the CYP2B1 promoter BTE (located between k82 and k67) reduced transcriptional activity 70-80 % in HepG2 cells [22] . Putative Sp1-binding sites are present at k45 to k36 and k79 to k70 of the CYP2B1 promoter, the latter within the BTE. Double-stranded oligonucleotides specifying either the k88\k65 or k48\k26 regions of the CYP2B1 promoter formed complexes with proteins present in rat liver nuclear extracts ( Figure 5 ). Proteins bound to these oligonucleotides were competed by a 100-fold molar excess of
Figure 5 Binding of Sp1 to two sites in the CYP2B1 proximal promoter
Rat liver nuclear protein extracts (NE, 14 µg) were incubated with 32 P-labelled double-stranded oligonucleotides, corresponding to sequences from k88 to k66 or k48 tok26 of the CYP2B1 proximal promoter, in the presence (j) or absence (k) of a 100-fold molar excess of an unlabelled double-stranded oligonucleotide competitor containing a consensus Sp1-binding site.
Figure 6 Stimulation of reporter-gene expression by Sp1
Primary rat hepatocytes were transfected with pGL3 Basic vector an oligonucleotide containing an Sp1-binding-site consensus sequence ( Figure 5) . Does Sp1 play a functional role in CYP2B1 expression or its induction by xenobiotics ? To address this, hepatocytes were cotransfected with an expression vector for Sp1 and a construct containing the luciferase gene under the control of the CYP2B1 proximal promoter either alone [(CYP2B1PP)-luc] or attached to the CYP2B1 PBRE [(CYP2B1PBRE)-PP-luc] (Figure 6 ). No stimulation of reporter-gene expression was observed in hepatocytes co-transfected with expression vectors for CAR or Sp1 and the reporter plasmid pGL3, which constitutes the backbone of (CYP2B1PP)-luc and (CYP2B1PBRE)-PP-luc (Figure 6a ). In cells transfected with (CYP2B1PP)-luc, reporter-gene expression was increased 27-fold by Sp1, but was unaffected by phenobarbital (Figure 6b ). Co-expression of CAR decreased the effect of Sp1 (Figure 6b ). Sp1 had a similar effect in cells transfected with (CYP2B1PBRE)-PP-luc. But, in this case, reporter-gene expression was increased a further 3-fold by phenobarbital (Figure 6c) . These results show that Sp1, by binding to sites within the proximal promoter of the CYP2B1 gene, increases basal transcription of the gene and, presumably via interaction with protein(s) bound to the CYP2B1 PBRE, stimulates the induction of gene expression in response to phenobarbital. Coexpression of CAR and Sp1 in hepatocytes transfected with (CYP2B1PBRE)-PP-luc resulted in no further enhancement of reporter-gene expression, in either the presence or absence of phenobarbital (Figure 6c ).
DISCUSSION
A previous study [26] used an indirect method to implicate CAR in the activation by phenobarbital of a CYP2B6 reporter-gene construct. Transfected HepG2 cells were first treated with androstenol, an inverse agonist of CAR, which represses constitutive activity of the receptor [25] . Subsequent treatment of the cells with phenobarbital increased reporter-gene expression, but only to the level observed in cells before androstenol treatment. Here we show directly that, in transfected primary hepatocytes and intact liver, constitutive CAR-mediated transactivation of a reporter gene linked to the CYP2B1 PBRE is increased in response to phenobarbital. An even larger increase was obtained in response to picrotoxin. CAR thus mediates the induction of CYP2B gene expression not only by phenobarbital, but also by other, structurally unrelated, compounds.
All three of the transformed cell lines used in our study, HepG2, HeLa and CV-1, were found to support constitutive activation of reporter-gene expression by co-transfected CAR. But, in contrast to primary hepatocytes and the intact liver, none was able to support an increase in CAR-mediated transactivation in response to phenobarbital. The ability of the transformed cell lines to regulate CAR-mediated activation of gene expression thus differs from that of liver in i o. In transformed cell lines, a signalling pathway that interacts with CAR may be permanently activated, thus preventing further activation in response to xenobiotics. Alternatively, such cells may lack a key component involved in modulating CAR activity. It is clear, therefore, that even liver-derived transformed cells, such as HepG2, are not good models for the xenobiotic induction of CAR-mediated transactivation of gene expression.
Nuclear receptors are thought to shuttle continually between the cytoplasm and the nucleus to maintain an equilibrium, which is perturbed in the presence of ligand [36] . It has been suggested that CAR is maintained in a repressed state in the cytoplasm and is translocated to the nucleus in response to phenobarbital [27] . However, the results of our co-transfection experiments show that, in primary hepatocytes and intact liver, CAR can enter the nucleus and transactivate gene expression via the PBRE in the absence of xenobiotics. Thus mechanisms other than, or in addition to, nuclear translocation of CAR may be responsible for the xenobiotic induction of gene expression via CAR.
We have found that CAR-mediated transactivation of gene expression via the PBRE is stimulated by the co-activator SRC-1. Furthermore, we show that, although the NR1 site of the PBRE is sufficient to support transactivation by CAR, additional sequences within the PBRE are required for the stimulation of this activity by SRC-1, and thus for the maximal induction of CYP2B1 in response to xenobiotics. That sequences other than NR1 may be important for the function of the PBRE has been suggested by the results of in i o DNA footprinting experiments [21] . These showed that, in rat liver, a footprint centred on the NF1 site of the PBRE expanded, in response to treatment of animals with phenobarbital, to encompass the whole of the adjacent NR1 and NR2 sites. Mutations of the NF1 site of the PBRE reduced responsiveness to phenobarbital of a reporter gene in primary hepatocytes [37, 38] but not in transgenic mice [39] . The contribution of the NF1 site to the function of the PBRE is thus unclear.
The results of our gel mobility-shift assays show that CAR binds, as a heterodimer with RXRα, to the NR1, but not to the NR2, site of the CYP2B1 PBRE, thus providing an explanation for why only the NR1 site of the PBRE is apparently necessary for CAR-mediated transactivation of the CYP2B1 gene. These results are in contrast to those of Tzamelli et al. [40] , who showed that CAR can heterodimerize with human RXRα on the NR2 site of the mouse Cyp2b10 gene. This discrepancy may be due to conformational differences adopted by CAR when heterodimerized to mouse RXRα (used by us) or to human RXRα (used by Tzameli et al. [40] ), or to the difference in sequence between the half-site spacer region of the rat and mouse NR2 sites. The human orthologue of CAR can bind to both the NR1 and NR2 sites of the human CYP2B6 PBRE [26] . This is probably due to differences between the nucleotide sequences of the rat and human NR2 sites : the human CYP2B6 NR2 is very similar in sequence to the CYP2B6 NR1, whereas the NR1 and NR2 of the rat CYP2B1 gene differ by two nucleotides in each of their half-sites and within the spacer region. This was confirmed by the finding that human CAR, produced by in itro transcription\translation, is able to bind to the NR1, but not the NR2, site of the CYP2B1 gene (results not shown). The apparent requirement of the NR2 site for stimulation of CAR-mediated transactivation by SRC-1 suggests that proteins that bind to this site may mediate the interaction between CAR, bound to the NR1 site, and SRC-1.
The mechanisms by which the barbiturate phenobarbital and the plant product picrotoxin induce CYP2B1 both involve the binding of CAR to the NR1 site of the PBRE. It seems likely that the induction mechanism utilized by these compounds evolved to enable animals to protect themselves against potentially harmful chemicals, such as picrotoxin, present in plants they ingest. It is fortuitous that a synthetic compound, such as phenobarbital, is able to use the same basic induction pathway.
Our results demonstrate that, by binding to sites within the proximal promoter of the CYP2B1 gene, the ubiquitous transcription factor Sp1 [28] increases both basal transcription and xenobiotic-induced expression via the PBRE. Sp1 may thus form a molecular bridge, allowing proteins bound to the PBRE to interact optimally with the transcriptional pre-initiation complex. For instance, Sp1 has been shown to interact with the Ah receptor and the Ah receptor nuclear translocator to increase the expression of CYP1A1 [41] . The identity of the protein(s) bound to the CYP2B1 PBRE that interact with Sp1 is not known. However, the lack of the effect of CAR on the activity of Sp1 implies that other proteins, possibly those that bind to the NR2 site, are involved. The changes that occur in the chromatin structure of the proximal promoter and PBRE of the CYP2B1 gene in response to phenobarbital [42] may aid recruitment of coactivators, such as SRC-1, and the interaction of PBRE-bound CYP2B1 gene regulation by CAR, SRC-1 and Sp1 proteins with transcription factors, such as Sp1, bound to the proximal promoter.
The identification of androstane metabolites as inverse agonists of the constitutive activity of CAR [25] raises the possibility that, in the liver, CYP2B1 gene expression is normally repressed by the presence of a compound that binds to and inactivates CAR, but can be displaced by certain xenobiotics. Although CYP2B1 can hydroxylate various steroids, including oestrogen and testosterone [43, 44] , the endogenous substrate(s) for this CYP are not known. Perhaps a hydroxylated steroid, a product of a reaction catalysed by CYP2B1 (or by another CYP), regulates CYP2B1 gene transcription via a feedback mechanism in which the metabolite, as its concentration rises, binds to CAR, thus preventing transactivation. A decrease in the concentration of the metabolite, or its displacement by a xenobiotic, would restore the ability of CAR to transactivate CYP gene expression through its interaction with the co-activator SRC-1. It will be of interest to determine whether compounds such as phenobarbital and picrotoxin bind directly to CAR, and whether this interaction displaces a CAR inhibitory compound similar to the steroids androstanol and androstenol. If this proves to be the case then the rationale for the dramatic increase in CYP gene expression in response to foreign chemicals may be to ensure the rapid removal of xenobiotics, thus allowing maintenance of steroid homoeostasis within organs such as the liver.
Phenobarbital has multiple effects in the liver : it causes proliferation of the endoplasmic reticulum, promotes tumour formation, dramatically increases liver size and regulates the expression of more than 30 genes [45] [46] [47] . It remains to be established whether all of these effects are mediated by CAR.
